Dr. Bahary on the Benefits of Ivosidenib in IDH1-Mutated Cholangiocarcinoma

Nathan Bahary, MD, PhD, an associate professor at the University of Pittsburgh School of Medicine, as well as a medical oncologist and hematologist at the University of Pittsburgh Medical Center​ Hillman Cancer Center, discusses the benefits of ivosidenib (Tibsovo) in patients with intrahepatic cholangiocarcinoma whose tumors harbor IDH1 mutations.

IDH1 mutations are known to occur in 10% to 13% of patients with intrahepatic cholangiocarcinoma, according to Bahary. 

Ivosidenib (Tibsovo) is 1 agent that is currently approved by the FDA for use in patients with IDH1-mutated acute myeloid leukemia. Another study examined the agent in patients with IDH1-mutated cholangiocarcinoma. Ivosidenib was found to improve progression-free survival and elicit durable responses in this population. Notably, this trial permitted crossover; thus, no confirmed overall survival benefit was noted, but benefit is possible given the extent of the mutations and the durability of responses to treatment, Bahary concludes.